Actithera
What They Do edit
Radiopharmaceutical company developing radioligand therapies for cancer treatment. Radioligand therapy targets cancer cells with radioactive compounds, offering precision treatment with fewer side effects than traditional chemotherapy.[1]
Revenue edit
Org nr: 935 938 341 Source: proff.no
- 2024: N/A (no accounts filed)
- Employees: 1-4
Founded May 2025. Radiopharmaceutical company developing radioligand therapies for cancer. Norwegian subsidiary of Actithera Group AS. US operations. $75.5M Series A (Jul 2025).
Funding edit
$75.5 million Series A (July 2025).[2]
Notably, Actithera secured this large Series A without a complete leadership team in place — defying typical VC expectations.[3] BioPharma Dive reported the company drew "new investors to radiopharma drug pitch."[4]
European Biotechnology Magazine noted the deal reflects "huge momentum" in radiopharma funding globally.[5]
See Also edit
- ↑ pharmaphorum (Jul 2025): "New radiopharma Actithera emerges with $75.5m in financing"
- ↑ ArcticStartup (Jul 10, 2025): "Norway & US-based Actithera raises $75.5M Series A to advance radioligand therapy pipeline"
- ↑ BioXconomy (2025): "Defying Series A odds: How Actithera secured $75.5m without a leadership team"
- ↑ BioPharma Dive (2025): "Actithera draws new investors to radiopharma drug pitch"
- ↑ European Biotechnology Magazine (2025): "Actithera: Radiopharma Funding Gathers Huge Momentum"